ES2815681T3 - Ureas cíclicas como inhibidores de ROCK - Google Patents
Ureas cíclicas como inhibidores de ROCK Download PDFInfo
- Publication number
- ES2815681T3 ES2815681T3 ES16703378T ES16703378T ES2815681T3 ES 2815681 T3 ES2815681 T3 ES 2815681T3 ES 16703378 T ES16703378 T ES 16703378T ES 16703378 T ES16703378 T ES 16703378T ES 2815681 T3 ES2815681 T3 ES 2815681T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- independently selected
- alkyl
- heterocyclyl
- nrara
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Cyclic ureas Chemical class 0.000 title description 117
- 239000011435 rock Substances 0.000 title description 40
- 239000003112 inhibitor Substances 0.000 title description 13
- 235000013877 carbamide Nutrition 0.000 title description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 167
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 164
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 148
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 147
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 146
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 144
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 134
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 99
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 96
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 95
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 83
- 229910021481 rutherfordium Inorganic materials 0.000 claims abstract description 83
- 101150105130 RORB gene Proteins 0.000 claims abstract description 76
- 229910052702 rhenium Inorganic materials 0.000 claims abstract description 68
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 61
- 150000003839 salts Chemical class 0.000 claims abstract description 54
- 125000003118 aryl group Chemical group 0.000 claims abstract description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 38
- 125000004452 carbocyclyl group Chemical group 0.000 claims abstract description 36
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 30
- 229910052701 rubidium Inorganic materials 0.000 claims abstract description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 22
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims abstract description 19
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims abstract description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 201
- 229910052799 carbon Inorganic materials 0.000 claims description 69
- 238000011282 treatment Methods 0.000 claims description 41
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 238000011321 prophylaxis Methods 0.000 claims description 9
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 9
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 9
- 208000006011 Stroke Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 210000002460 smooth muscle Anatomy 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 150000004885 piperazines Chemical class 0.000 claims description 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 230000000771 oncological effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 304
- 238000000034 method Methods 0.000 description 222
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 187
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 178
- 239000011541 reaction mixture Substances 0.000 description 157
- 239000000243 solution Substances 0.000 description 154
- 238000005160 1H NMR spectroscopy Methods 0.000 description 151
- 239000007787 solid Substances 0.000 description 146
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 132
- 235000019439 ethyl acetate Nutrition 0.000 description 124
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 114
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 103
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 102
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 100
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 79
- 239000000460 chlorine Substances 0.000 description 77
- 238000002360 preparation method Methods 0.000 description 77
- 238000004128 high performance liquid chromatography Methods 0.000 description 76
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 72
- 239000011734 sodium Substances 0.000 description 69
- 239000002904 solvent Substances 0.000 description 68
- 239000012267 brine Substances 0.000 description 65
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 65
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- 239000000543 intermediate Substances 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 43
- 238000003818 flash chromatography Methods 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 42
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 239000012043 crude product Substances 0.000 description 37
- 238000002953 preparative HPLC Methods 0.000 description 37
- 229910000104 sodium hydride Inorganic materials 0.000 description 36
- 239000012391 XPhos Pd G2 Substances 0.000 description 35
- 239000000706 filtrate Substances 0.000 description 35
- 239000012044 organic layer Substances 0.000 description 35
- 239000000047 product Substances 0.000 description 34
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 27
- 239000012453 solvate Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 238000010828 elution Methods 0.000 description 23
- 238000000746 purification Methods 0.000 description 23
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 20
- 239000002585 base Substances 0.000 description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 239000006184 cosolvent Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 238000004293 19F NMR spectroscopy Methods 0.000 description 16
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 229910052717 sulfur Inorganic materials 0.000 description 15
- 238000001914 filtration Methods 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 238000004808 supercritical fluid chromatography Methods 0.000 description 14
- FCXAYEPBCJFGPO-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C(O)=O)N=C1 FCXAYEPBCJFGPO-UHFFFAOYSA-N 0.000 description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 229910052796 boron Inorganic materials 0.000 description 12
- GRRIMVWABNHKBX-UHFFFAOYSA-N (3-methoxyphenyl)methanamine Chemical compound COC1=CC=CC(CN)=C1 GRRIMVWABNHKBX-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- CZQIJQFTRGDODI-UHFFFAOYSA-N 1-bromo-4-isocyanatobenzene Chemical compound BrC1=CC=C(N=C=O)C=C1 CZQIJQFTRGDODI-UHFFFAOYSA-N 0.000 description 8
- PHRJTGPFEAUEBC-UHFFFAOYSA-N 1-fluoro-3-(isocyanatomethyl)benzene Chemical compound FC1=CC=CC(CN=C=O)=C1 PHRJTGPFEAUEBC-UHFFFAOYSA-N 0.000 description 8
- SIOHQNFGXFYSHG-UHFFFAOYSA-N 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-2-(3-methoxyphenyl)acetic acid Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(C(=O)O)C1=CC(=CC=C1)OC)=O SIOHQNFGXFYSHG-UHFFFAOYSA-N 0.000 description 8
- 101150065749 Churc1 gene Proteins 0.000 description 8
- 229910004298 SiO 2 Inorganic materials 0.000 description 8
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 8
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 8
- 239000012948 isocyanate Substances 0.000 description 8
- 150000002513 isocyanates Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002480 mineral oil Substances 0.000 description 8
- 235000010446 mineral oil Nutrition 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000012312 sodium hydride Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 238000001665 trituration Methods 0.000 description 8
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 125000002619 bicyclic group Chemical group 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- BAFHKFIYBFCXAU-UHFFFAOYSA-N (2-fluoro-5-methoxyphenyl)methanamine Chemical compound COC1=CC=C(F)C(CN)=C1 BAFHKFIYBFCXAU-UHFFFAOYSA-N 0.000 description 6
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 6
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 101150111584 RHOA gene Proteins 0.000 description 6
- 238000006069 Suzuki reaction reaction Methods 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 230000029936 alkylation Effects 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 239000012039 electrophile Substances 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- PUBVIAHPSLGSFN-UHFFFAOYSA-N phenyl n-(5-bromopyridin-2-yl)carbamate Chemical compound N1=CC(Br)=CC=C1NC(=O)OC1=CC=CC=C1 PUBVIAHPSLGSFN-UHFFFAOYSA-N 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- QVSVMNXRLWSNGS-UHFFFAOYSA-N (3-fluorophenyl)methanamine Chemical compound NCC1=CC=CC(F)=C1 QVSVMNXRLWSNGS-UHFFFAOYSA-N 0.000 description 5
- KHWUOEFJPTYZGZ-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[(3-fluorophenyl)methyl]imidazol-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(C=C1)CC1=CC(=CC=C1)F)=O KHWUOEFJPTYZGZ-UHFFFAOYSA-N 0.000 description 5
- QWGAJMDRYUIPIT-UHFFFAOYSA-N 1-(isocyanatomethyl)-3-methoxybenzene Chemical group COC1=CC=CC(CN=C=O)=C1 QWGAJMDRYUIPIT-UHFFFAOYSA-N 0.000 description 5
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 5
- VCYCTWDKBKJCME-UHFFFAOYSA-N 3-(4-bromophenyl)-4-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1CO)CC1=CC(=CC=C1)OC)=O VCYCTWDKBKJCME-UHFFFAOYSA-N 0.000 description 5
- VAFZZUKCXFHFMN-UHFFFAOYSA-N BrC1=CC=C(C=C1)NC(=O)NCC(OC)OC Chemical compound BrC1=CC=C(C=C1)NC(=O)NCC(OC)OC VAFZZUKCXFHFMN-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- OENICUBCLXKLJQ-UHFFFAOYSA-N ethyl 2,3-dibromopropanoate Chemical compound CCOC(=O)C(Br)CBr OENICUBCLXKLJQ-UHFFFAOYSA-N 0.000 description 5
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 201000001881 impotence Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012299 nitrogen atmosphere Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 5
- 125000004434 sulfur atom Chemical group 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 5
- CJWGCBRQAHCVHW-SSDOTTSWSA-N (1r)-1-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC([C@@H](C)N)=C1 CJWGCBRQAHCVHW-SSDOTTSWSA-N 0.000 description 4
- SERVOTWJOQLFFE-QMMMGPOBSA-N (5S)-3-(4-bromophenyl)-5-(hydroxymethyl)imidazolidine-2,4-dione Chemical compound BrC1=CC=C(C=C1)N1C(N[C@H](C1=O)CO)=O SERVOTWJOQLFFE-QMMMGPOBSA-N 0.000 description 4
- BSSSIZYVYOYHRG-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[2-hydroxy-1-(3-methoxyphenyl)ethyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(CO)C1=CC(=CC=C1)OC)=O BSSSIZYVYOYHRG-UHFFFAOYSA-N 0.000 description 4
- IQYIOVFMXOWYEQ-UHFFFAOYSA-N 1-(4-bromophenyl)imidazolidin-2-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)NCC1 IQYIOVFMXOWYEQ-UHFFFAOYSA-N 0.000 description 4
- MNXTVUMNYVTDPV-UHFFFAOYSA-N 1-[2-methoxy-1-(3-methoxyphenyl)ethyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)C(COC)C1=CC(=CC=C1)OC)=O MNXTVUMNYVTDPV-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 4
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 4
- QGQSOHAZQJREQX-UHFFFAOYSA-N 3-(4-bromophenyl)-1-[(3-methoxyphenyl)methyl]-2-oxoimidazolidine-4-carboxylic acid Chemical compound COC1=CC=CC(CN2CC(N(C2=O)C2=CC=C(Br)C=C2)C(O)=O)=C1 QGQSOHAZQJREQX-UHFFFAOYSA-N 0.000 description 4
- XYNBYRIOJLMJDM-UHFFFAOYSA-N 3-(4-bromophenyl)-1h-imidazol-2-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)NC=C1 XYNBYRIOJLMJDM-UHFFFAOYSA-N 0.000 description 4
- YFLOLCNMBKTBQE-UHFFFAOYSA-N 4-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1CO)CC1=CC(=CC=C1)OC)=O YFLOLCNMBKTBQE-UHFFFAOYSA-N 0.000 description 4
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 4
- CRIXOEJNMCGMFU-UHFFFAOYSA-N BrC1=CC=C(C=C1)NC(=O)NC(CO)(C)C Chemical compound BrC1=CC=C(C=C1)NC(=O)NC(CO)(C)C CRIXOEJNMCGMFU-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 150000001204 N-oxides Chemical class 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 4
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 description 4
- 229960002435 fasudil Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000002541 furyl group Chemical group 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 208000001286 intracranial vasospasm Diseases 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- 125000004306 triazinyl group Chemical group 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- HPNFVYCKGVTLQR-FQEVSTJZSA-N (4S)-1-(5-bromopyridin-2-yl)-3-[(4-fluoro-3-methoxyphenyl)methyl]-4-(phenylmethoxymethyl)imidazolidin-2-one Chemical compound C(C1=CC=CC=C1)OC[C@H]1N(C(N(C1)C1=NC=C(C=C1)Br)=O)CC1=CC(=C(C=C1)F)OC HPNFVYCKGVTLQR-FQEVSTJZSA-N 0.000 description 3
- NUSSSWUWRFNZSF-AWEZNQCLSA-N (4S)-1-(5-bromopyridin-2-yl)-4-(phenylmethoxymethyl)imidazolidin-2-one Chemical compound C(C1=CC=CC=C1)OC[C@H]1NC(N(C1)C1=NC=C(C=C1)Br)=O NUSSSWUWRFNZSF-AWEZNQCLSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- MCZOJSVFRSKRIT-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[(3-methoxyphenyl)methyl]-4,4-dimethylimidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(C(C1)(C)C)CC1=CC(=CC=C1)OC)=O MCZOJSVFRSKRIT-UHFFFAOYSA-N 0.000 description 3
- NKSKBHOFUFHTQW-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[1-(3-methoxyphenyl)-2-(methylamino)ethyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(CNC)C1=CC(=CC=C1)OC)=O NKSKBHOFUFHTQW-UHFFFAOYSA-N 0.000 description 3
- XOAWAEJRZAUCBQ-UHFFFAOYSA-N 1-(4-bromophenyl)-4,4-dimethylimidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(NC(C1)(C)C)=O XOAWAEJRZAUCBQ-UHFFFAOYSA-N 0.000 description 3
- HZGFMAINEPFALC-UHFFFAOYSA-N 1-(5-bromo-4-fluoropyridin-2-yl)-3-(2-chloroethyl)urea Chemical compound BrC=1C(=CC(=NC=1)NC(=O)NCCCl)F HZGFMAINEPFALC-UHFFFAOYSA-N 0.000 description 3
- NMJLMTJOGLHZFG-UHFFFAOYSA-N 1-(5-bromo-6-methoxypyridin-2-yl)-3-(2-chloroethyl)urea Chemical compound BrC=1C=CC(=NC=1OC)NC(=O)NCCCl NMJLMTJOGLHZFG-UHFFFAOYSA-N 0.000 description 3
- AJVYTJKQVYHHFD-UHFFFAOYSA-N 1-(5-bromo-6-methoxypyridin-2-yl)-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC=1C=CC(=NC=1OC)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O AJVYTJKQVYHHFD-UHFFFAOYSA-N 0.000 description 3
- QXPLHQMBJXUDBM-UHFFFAOYSA-N 1-(5-bromo-6-methoxypyridin-2-yl)imidazolidin-2-one Chemical compound BrC=1C=CC(=NC=1OC)N1C(NCC1)=O QXPLHQMBJXUDBM-UHFFFAOYSA-N 0.000 description 3
- CKPQCRZJUMIZSZ-UHFFFAOYSA-N 1-(5-bromopyridin-2-yl)-3-(2,2-dimethoxyethyl)urea Chemical compound BrC=1C=CC(=NC=1)NC(=O)NCC(OC)OC CKPQCRZJUMIZSZ-UHFFFAOYSA-N 0.000 description 3
- IRPQETWLVOSUFU-AWEZNQCLSA-N 1-(5-bromopyridin-2-yl)-3-[(2S)-1-hydroxy-3-phenylmethoxypropan-2-yl]urea Chemical compound C(C1=CC=CC=C1)OC[C@H](CO)NC(=O)NC1=NC=C(C=C1)Br IRPQETWLVOSUFU-AWEZNQCLSA-N 0.000 description 3
- NNBQSRWXJWCBRZ-OAHLLOKOSA-N 1-[(1R)-1-(3-methoxyphenyl)ethyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)[C@H](C)C1=CC(=CC=C1)OC)=O NNBQSRWXJWCBRZ-OAHLLOKOSA-N 0.000 description 3
- AYQLRXTWBJMVHE-UHFFFAOYSA-N 1-[2-hydroxy-1-(3-methoxyphenyl)ethyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)C(CO)C1=CC(=CC=C1)OC)=O AYQLRXTWBJMVHE-UHFFFAOYSA-N 0.000 description 3
- 125000005955 1H-indazolyl group Chemical group 0.000 description 3
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- NWSPYGGFNRLOII-UHFFFAOYSA-N 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-2-(3-methoxyphenyl)-N-methylacetamide Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(C(=O)NC)C1=CC(=CC=C1)OC)=O NWSPYGGFNRLOII-UHFFFAOYSA-N 0.000 description 3
- GLDACSZMLWTLKU-UHFFFAOYSA-N 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-2-(3-methoxyphenyl)propanoic acid Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(C(=O)O)(C)C1=CC(=CC=C1)OC)=O GLDACSZMLWTLKU-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- OHGHOAABSRQUAT-UHFFFAOYSA-N 3-[(3-methoxyphenyl)methyl]-4,4-dimethyl-1-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C(C1)(C)C)CC1=CC(=CC=C1)OC)=O OHGHOAABSRQUAT-UHFFFAOYSA-N 0.000 description 3
- LKJYNYKTZLTHJN-UHFFFAOYSA-N 3-cyclopropylaniline Chemical compound NC1=CC=CC(C2CC2)=C1 LKJYNYKTZLTHJN-UHFFFAOYSA-N 0.000 description 3
- TVOJIBGZFYMWDT-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CNN=C1 TVOJIBGZFYMWDT-UHFFFAOYSA-N 0.000 description 3
- NDCFPYSZIBBKFT-UHFFFAOYSA-N 4-(hydroxymethyl)-3-[(3-methoxyphenyl)methyl]-1-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C(C1)CO)CC1=CC(=CC=C1)OC)=O NDCFPYSZIBBKFT-UHFFFAOYSA-N 0.000 description 3
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 3
- LGSYJKNZJDHFDF-UHFFFAOYSA-N 5-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C(C1=O)CO)CC1=CC(=CC=C1)OC)=O LGSYJKNZJDHFDF-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 206010003225 Arteriospasm coronary Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000003890 Coronary Vasospasm Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000011634 coronary artery vasospasm Diseases 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- XXBNIZMWCZGAQO-JTQLQIEISA-N ethyl (2S)-2-[(4-bromophenyl)carbamoylamino]-3-hydroxypropanoate Chemical compound BrC1=CC=C(C=C1)NC(N[C@H](C(=O)OCC)CO)=O XXBNIZMWCZGAQO-JTQLQIEISA-N 0.000 description 3
- GKCXXDSWWDWUHS-BYPYZUCNSA-N ethyl (2s)-2-amino-3-hydroxypropanoate Chemical compound CCOC(=O)[C@@H](N)CO GKCXXDSWWDWUHS-BYPYZUCNSA-N 0.000 description 3
- XQTDJCPVBBMKQC-UHFFFAOYSA-N ethyl 3-(4-bromophenyl)-1-[(3-methoxyphenyl)methyl]-2-oxoimidazolidine-4-carboxylate Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1C(=O)OCC)CC1=CC(=CC=C1)OC)=O XQTDJCPVBBMKQC-UHFFFAOYSA-N 0.000 description 3
- PDFLNJUJXGLBPQ-UHFFFAOYSA-N ethyl 3-[(4-bromophenyl)carbamoyl-[(3-methoxyphenyl)methyl]amino]-2-chloropropanoate Chemical compound BrC1=CC=C(C=C1)NC(N(CC1=CC(=CC=C1)OC)CC(C(=O)OCC)Cl)=O PDFLNJUJXGLBPQ-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000004047 hyperresponsiveness Effects 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- PVPRFDHZRBRHAN-UHFFFAOYSA-N methyl 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-2-(3-methoxyphenyl)propanoate Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(C(=O)OC)(C)C1=CC(=CC=C1)OC)=O PVPRFDHZRBRHAN-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- CWPBIJUKARSYKD-UHFFFAOYSA-N tert-butyl N-(4-bromo-3-cyclopropylphenyl)carbamate Chemical compound BrC1=C(C=C(C=C1)NC(OC(C)(C)C)=O)C1CC1 CWPBIJUKARSYKD-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- LRFWYBZWRQWZIM-UHFFFAOYSA-N (2-fluorophenyl)methanamine Chemical compound NCC1=CC=CC=C1F LRFWYBZWRQWZIM-UHFFFAOYSA-N 0.000 description 2
- AAZCFOYBTCRVEJ-YUMQZZPRSA-N (2S,5S)-2,5-diethylphospholane Chemical compound CC[C@H]1CC[C@H](CC)P1 AAZCFOYBTCRVEJ-YUMQZZPRSA-N 0.000 description 2
- CWRWOJOKTRDGBA-QHCPKHFHSA-N (4S)-3-[(4-fluoro-3-methoxyphenyl)methyl]-4-(phenylmethoxymethyl)-1-[5-(1H-pyrazol-4-yl)pyridin-2-yl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C=1C=CC(=NC=1)N1C(N([C@@H](C1)COCC1=CC=CC=C1)CC1=CC(=C(C=C1)F)OC)=O CWRWOJOKTRDGBA-QHCPKHFHSA-N 0.000 description 2
- KEVZSEIFNDIJIH-INIZCTEOSA-N (5S)-3-(4-bromophenyl)-5-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]imidazolidine-2,4-dione Chemical compound BrC1=CC=C(C=C1)N1C(N([C@H](C1=O)CO)CC1=CC(=CC=C1)OC)=O KEVZSEIFNDIJIH-INIZCTEOSA-N 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- TZFCICDGDYSTCO-CYBMUJFWSA-N 1-(4-bromophenyl)-1-(2-chloroethyl)-3-[(1R)-1-(3-methoxyphenyl)ethyl]urea Chemical compound BrC1=CC=C(C=C1)N(C(=O)N[C@H](C)C1=CC(=CC=C1)OC)CCCl TZFCICDGDYSTCO-CYBMUJFWSA-N 0.000 description 2
- WEBSBVNASIARDC-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(2-chloroethyl)urea Chemical compound ClCCNC(=O)NC1=CC=C(Br)C=C1 WEBSBVNASIARDC-UHFFFAOYSA-N 0.000 description 2
- RDDYFVDFDWOHSP-UHFFFAOYSA-N 1-(4-bromophenyl)-4-(2-hydroxypropan-2-yl)-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(C(C1)C(C)(C)O)CC1=CC(=CC=C1)OC)=O RDDYFVDFDWOHSP-UHFFFAOYSA-N 0.000 description 2
- MLBLLDLHRJCOIB-UHFFFAOYSA-N 1-(5-bromo-4-fluoropyridin-2-yl)imidazolidin-2-one Chemical compound BrC=1C(=CC(=NC=1)N1C(NCC1)=O)F MLBLLDLHRJCOIB-UHFFFAOYSA-N 0.000 description 2
- UZPHQWVNBDGGCU-UHFFFAOYSA-N 1-(5-bromo-4-methylpyridin-2-yl)-3-(2-chloroethyl)urea Chemical compound BrC=1C(=CC(=NC=1)NC(=O)NCCCl)C UZPHQWVNBDGGCU-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HHWDCAKVSSSKCZ-UHFFFAOYSA-N 1-[(2-fluoro-5-methoxyphenyl)methyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound FC1=C(CN2C(N(CC2)C2=CC(=C(C=C2)C=2C=NNC=2)OC)=O)C=C(C=C1)OC HHWDCAKVSSSKCZ-UHFFFAOYSA-N 0.000 description 2
- OOFVDIINTYBOKP-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC1=CC=CC(CN2CCN(C2=O)C2=C(OC)C=C(C=C2)C2=CNN=C2)=C1 OOFVDIINTYBOKP-UHFFFAOYSA-N 0.000 description 2
- KUGVYROMWMFUNT-UHFFFAOYSA-N 1-[5-(3-fluoropyridin-4-yl)-6-methoxypyridin-2-yl]-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound FC=1C=NC=CC=1C=1C(=NC(=CC=1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O)OC KUGVYROMWMFUNT-UHFFFAOYSA-N 0.000 description 2
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 2
- ZMYAKSMZTVWUJB-UHFFFAOYSA-M 2,3-dibromopropanoate Chemical compound [O-]C(=O)C(Br)CBr ZMYAKSMZTVWUJB-UHFFFAOYSA-M 0.000 description 2
- OEZPGBYRQQBYMV-UHFFFAOYSA-N 2-(3-methoxyphenyl)-N-methyl-2-[2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-1-yl]propanamide Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)C(C(=O)NC)(C)C1=CC(=CC=C1)OC)=O OEZPGBYRQQBYMV-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- HBWXWGQFMNTOIZ-UHFFFAOYSA-N 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-N-ethyl-2-(3-methoxyphenyl)acetamide Chemical compound CCNC(=O)C(N1CCN(C1=O)C1=CC=C(Br)C=C1)C1=CC(OC)=CC=C1 HBWXWGQFMNTOIZ-UHFFFAOYSA-N 0.000 description 2
- HACRKYQRZABURO-UHFFFAOYSA-N 2-phenylethyl isocyanate Chemical compound O=C=NCCC1=CC=CC=C1 HACRKYQRZABURO-UHFFFAOYSA-N 0.000 description 2
- KEVZSEIFNDIJIH-UHFFFAOYSA-N 3-(4-bromophenyl)-5-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]imidazolidine-2,4-dione Chemical compound BrC1=CC=C(C=C1)N1C(N(C(C1=O)CO)CC1=CC(=CC=C1)OC)=O KEVZSEIFNDIJIH-UHFFFAOYSA-N 0.000 description 2
- XJEJLZQJTWXQAB-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)-1H-imidazol-2-one Chemical compound BrC=1C=CC(=NC=1)N1C(NC=C1)=O XJEJLZQJTWXQAB-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- VUHMKNHUHMYLFV-UHFFFAOYSA-N 4-(2-hydroxypropan-2-yl)-3-[(3-methoxyphenyl)methyl]-1-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C(C1)C(C)(C)O)CC1=CC(=CC=C1)OC)=O VUHMKNHUHMYLFV-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- WRFYIYOXJWKONR-UHFFFAOYSA-N 4-bromo-2-methoxyaniline Chemical compound COC1=CC(Br)=CC=C1N WRFYIYOXJWKONR-UHFFFAOYSA-N 0.000 description 2
- UVDWSNIVPGNZFL-UHFFFAOYSA-N 4-bromo-3-cyclopropylaniline Chemical compound NC1=CC=C(Br)C(C2CC2)=C1 UVDWSNIVPGNZFL-UHFFFAOYSA-N 0.000 description 2
- RUTNWXBHRAIQSP-UHFFFAOYSA-N 4-bromo-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Br RUTNWXBHRAIQSP-UHFFFAOYSA-N 0.000 description 2
- NTZTWGPSRYUWFM-UHFFFAOYSA-N 4-bromo-N-(2-chloroethyl)-3-methoxyaniline Chemical compound BrC1=C(C=C(NCCCl)C=C1)OC NTZTWGPSRYUWFM-UHFFFAOYSA-N 0.000 description 2
- XIXFJFPXOWYEJY-UHFFFAOYSA-N 4-bromo-n-(2-chloroethyl)aniline Chemical compound ClCCNC1=CC=C(Br)C=C1 XIXFJFPXOWYEJY-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 2
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical class OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 2
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IXMVSHLVCSJCQJ-CQSZACIVSA-N BrC1=CC=C(C=C1)NC(=O)N[C@@H](CO[Si](C)(C)C(C)(C)C)CO Chemical compound BrC1=CC=C(C=C1)NC(=O)N[C@@H](CO[Si](C)(C)C(C)(C)C)CO IXMVSHLVCSJCQJ-CQSZACIVSA-N 0.000 description 2
- 201000000057 Coronary Stenosis Diseases 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical group NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000011111 cardboard Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- RNCZPRFKCVSQFD-UHFFFAOYSA-N ethyl 1-(4-bromophenyl)-3-[(3-methoxyphenyl)methyl]-2-oxoimidazolidine-4-carboxylate Chemical compound BrC1=CC=C(C=C1)N1C(N(C(C1)C(=O)OCC)CC1=CC(=CC=C1)OC)=O RNCZPRFKCVSQFD-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 2
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical group O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 2
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- PSYWPDSYDAKOJA-UHFFFAOYSA-N methyl 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-2-(3-methoxyphenyl)acetate Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(C(=O)OC)C1=CC(=CC=C1)OC)=O PSYWPDSYDAKOJA-UHFFFAOYSA-N 0.000 description 2
- YWMCHHGKDMGQPQ-UHFFFAOYSA-N methyl 2-bromo-2-(3-methoxyphenyl)acetate Chemical compound COC(=O)C(Br)C1=CC=CC(OC)=C1 YWMCHHGKDMGQPQ-UHFFFAOYSA-N 0.000 description 2
- DOYKYXMRPXMHLZ-UHFFFAOYSA-N methyl 3-amino-3-(3-methoxyphenyl)propanoate Chemical group COC(=O)CC(N)C1=CC=CC(OC)=C1 DOYKYXMRPXMHLZ-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000008692 neointimal formation Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000009117 preventive therapy Methods 0.000 description 2
- 238000011324 primary prophylaxis Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 150000003413 spiro compounds Chemical class 0.000 description 2
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- PQCUDKMMPTXMAL-UHFFFAOYSA-N (2,6-difluorophenyl)methanamine Chemical compound NCC1=C(F)C=CC=C1F PQCUDKMMPTXMAL-UHFFFAOYSA-N 0.000 description 1
- KDDNKZCVYQDGKE-UHFFFAOYSA-N (2-chlorophenyl)methanamine Chemical compound NCC1=CC=CC=C1Cl KDDNKZCVYQDGKE-UHFFFAOYSA-N 0.000 description 1
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJWHQBTUHVIRJJ-PPHPATTJSA-N (2s)-2-amino-3-phenylmethoxypropan-1-ol;hydrochloride Chemical compound Cl.OC[C@H](N)COCC1=CC=CC=C1 BJWHQBTUHVIRJJ-PPHPATTJSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- QUHSESYLMZVXCN-UHFFFAOYSA-N (3-fluoropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC=NC=C1F QUHSESYLMZVXCN-UHFFFAOYSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- FZUXLJASNZTFSZ-MRXNPFEDSA-N (4R)-1-(4-bromophenyl)-4-(hydroxymethyl)-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N([C@H](C1)CO)CC1=CC(=CC=C1)OC)=O FZUXLJASNZTFSZ-MRXNPFEDSA-N 0.000 description 1
- NDCFPYSZIBBKFT-LJQANCHMSA-N (4R)-4-(hydroxymethyl)-3-[(3-methoxyphenyl)methyl]-1-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N([C@H](C1)CO)CC1=CC(=CC=C1)OC)=O NDCFPYSZIBBKFT-LJQANCHMSA-N 0.000 description 1
- JDVUMNUUUJSWKP-INIZCTEOSA-N (4S)-3-[(4-fluoro-3-methoxyphenyl)methyl]-4-(hydroxymethyl)-1-[5-(1H-pyrazol-4-yl)pyridin-2-yl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C=1C=CC(=NC=1)N1C(N([C@@H](C1)CO)CC1=CC(=C(C=C1)F)OC)=O JDVUMNUUUJSWKP-INIZCTEOSA-N 0.000 description 1
- SQBOSZXDOHQFAA-SEVDZJIVSA-N (4r,5r,6r,7r)-1,3-dibenzyl-5,6-dihydroxy-4,7-bis(phenoxymethyl)-1,3-diazepan-2-one Chemical compound C([C@@H]1[C@@H](O)[C@@H]([C@H](N(CC=2C=CC=CC=2)C(=O)N1CC=1C=CC=CC=1)COC=1C=CC=CC=1)O)OC1=CC=CC=C1 SQBOSZXDOHQFAA-SEVDZJIVSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- UIIJKBSUGZNVQN-UHFFFAOYSA-N 1-(2-bromoethyl)-2-methoxybenzene Chemical compound COC1=CC=CC=C1CCBr UIIJKBSUGZNVQN-UHFFFAOYSA-N 0.000 description 1
- COGKCVIZDSDFHI-UHFFFAOYSA-N 1-(2-phenylethyl)-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)CCC1=CC=CC=C1)=O COGKCVIZDSDFHI-UHFFFAOYSA-N 0.000 description 1
- DGGRDUPQQAZJQY-UHFFFAOYSA-N 1-(4-bromo-2-methoxyphenyl)-1-(2-chloroethyl)-3-[(3-fluorophenyl)methyl]urea Chemical compound BrC1=CC(=C(C=C1)N(C(=O)NCC1=CC(=CC=C1)F)CCCl)OC DGGRDUPQQAZJQY-UHFFFAOYSA-N 0.000 description 1
- NNNYSDGVSDTRHQ-UHFFFAOYSA-N 1-(4-bromo-2-methoxyphenyl)-3-[(3-fluorophenyl)methyl]imidazolidin-2-one Chemical compound BrC1=CC(=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)F)=O)OC NNNYSDGVSDTRHQ-UHFFFAOYSA-N 0.000 description 1
- ZFRQKSSARXFRCG-UHFFFAOYSA-N 1-(4-bromo-3-ethylphenyl)-1-(2-chloroethyl)-3-[(3-methoxyphenyl)methyl]urea Chemical compound BrC1=C(C=C(C=C1)N(C(=O)NCC1=CC(=CC=C1)OC)CCCl)CC ZFRQKSSARXFRCG-UHFFFAOYSA-N 0.000 description 1
- AEQLCUFHTKMUCJ-UHFFFAOYSA-N 1-(4-bromo-3-ethylphenyl)-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=C(C=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O)CC AEQLCUFHTKMUCJ-UHFFFAOYSA-N 0.000 description 1
- RXXLOHMFXXJWHV-CYBMUJFWSA-N 1-(4-bromo-3-methoxyphenyl)-1-(2-chloroethyl)-3-[(1R)-1-(3-methoxyphenyl)ethyl]urea Chemical compound BrC1=C(C=C(C=C1)N(C(=O)N[C@H](C)C1=CC(=CC=C1)OC)CCCl)OC RXXLOHMFXXJWHV-CYBMUJFWSA-N 0.000 description 1
- BFXUJCLRNMNMDW-UHFFFAOYSA-N 1-(4-bromo-3-methoxyphenyl)-1-(2-chloroethyl)-3-[(2-fluoro-5-methoxyphenyl)methyl]urea Chemical compound BrC1=C(C=C(C=C1)N(C(=O)NCC1=C(C=CC(=C1)OC)F)CCCl)OC BFXUJCLRNMNMDW-UHFFFAOYSA-N 0.000 description 1
- IZPRJISEQYKMHD-UHFFFAOYSA-N 1-(4-bromo-3-methoxyphenyl)-1-(2-chloroethyl)-3-[(3-fluorophenyl)methyl]urea Chemical compound BrC1=C(C=C(C=C1)N(C(=O)NCC1=CC(=CC=C1)F)CCCl)OC IZPRJISEQYKMHD-UHFFFAOYSA-N 0.000 description 1
- TYPKFBQSXUKNHA-CYBMUJFWSA-N 1-(4-bromo-3-methoxyphenyl)-3-[(1R)-1-(3-methoxyphenyl)ethyl]imidazolidin-2-one Chemical compound BrC1=C(C=C(C=C1)N1C(N(CC1)[C@H](C)C1=CC(=CC=C1)OC)=O)OC TYPKFBQSXUKNHA-CYBMUJFWSA-N 0.000 description 1
- XSVLKZQXPUILGI-UHFFFAOYSA-N 1-(4-bromo-3-methoxyphenyl)-3-[(2-fluoro-5-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=C(C=C(C=C1)N1C(N(CC1)CC1=C(C=CC(=C1)OC)F)=O)OC XSVLKZQXPUILGI-UHFFFAOYSA-N 0.000 description 1
- OUGWHKSVLQVDCC-UHFFFAOYSA-N 1-(4-bromo-3-methoxyphenyl)-3-[3-hydroxy-1-(3-methoxyphenyl)-3-methylbutyl]imidazolidin-2-one Chemical compound BrC1=C(C=C(C=C1)N1C(N(CC1)C(CC(C)(C)O)C1=CC(=CC=C1)OC)=O)OC OUGWHKSVLQVDCC-UHFFFAOYSA-N 0.000 description 1
- OOUCBNBSUFSKRS-UHFFFAOYSA-N 1-(4-bromo-3-methoxyphenyl)-3-[3-hydroxy-1-(3-methoxyphenyl)propyl]imidazolidin-2-one Chemical compound BrC1=C(C=C(C=C1)N1C(N(CC1)C(CCO)C1=CC(=CC=C1)OC)=O)OC OOUCBNBSUFSKRS-UHFFFAOYSA-N 0.000 description 1
- PFKFBFMSSQETNP-UHFFFAOYSA-N 1-(4-bromo-3-methoxyphenyl)imidazolidine-2,4-dione Chemical compound C1=C(Br)C(OC)=CC(N2C(NC(=O)C2)=O)=C1 PFKFBFMSSQETNP-UHFFFAOYSA-N 0.000 description 1
- ZAJXQINKXUAWJJ-UHFFFAOYSA-N 1-(4-bromophenyl)-1-(2-chloroethyl)-3-(2-phenylethyl)urea Chemical compound BrC1=CC=C(C=C1)N(C(=O)NCCC1=CC=CC=C1)CCCl ZAJXQINKXUAWJJ-UHFFFAOYSA-N 0.000 description 1
- PWNKYCIDSZTIOF-UHFFFAOYSA-N 1-(4-bromophenyl)-3-(2-phenylethyl)imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)CCC1=CC=CC=C1)=O PWNKYCIDSZTIOF-UHFFFAOYSA-N 0.000 description 1
- PVYONXVJSUIHAF-CYBMUJFWSA-N 1-(4-bromophenyl)-3-[(1R)-1-(3-methoxyphenyl)ethyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)[C@H](C)C1=CC(=CC=C1)OC)=O PVYONXVJSUIHAF-CYBMUJFWSA-N 0.000 description 1
- PXKIBFIJNCCZEX-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[(2-fluoro-3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)CC1=C(C(=CC=C1)OC)F)=O PXKIBFIJNCCZEX-UHFFFAOYSA-N 0.000 description 1
- WRXPWZKUFYCYKU-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O WRXPWZKUFYCYKU-UHFFFAOYSA-N 0.000 description 1
- QMJUROHCICDVFF-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[2-(2-methoxyphenyl)ethyl]imidazol-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(C=C1)CCC1=C(C=CC=C1)OC)=O QMJUROHCICDVFF-UHFFFAOYSA-N 0.000 description 1
- WGZLOQZMQMXWOJ-UHFFFAOYSA-N 1-(4-bromophenyl)-3-[2-methoxy-1-(3-methoxyphenyl)ethyl]imidazolidin-2-one Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(COC)C1=CC(=CC=C1)OC)=O WGZLOQZMQMXWOJ-UHFFFAOYSA-N 0.000 description 1
- AFJSFTQVPPXCRQ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluoro-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1F AFJSFTQVPPXCRQ-UHFFFAOYSA-N 0.000 description 1
- SCBZBMXPJYMXRC-UHFFFAOYSA-N 1-(bromomethyl)-3-fluorobenzene Chemical compound FC1=CC=CC(CBr)=C1 SCBZBMXPJYMXRC-UHFFFAOYSA-N 0.000 description 1
- XTEIMRMVNBUQSJ-OAHLLOKOSA-N 1-[(1R)-1-(3-methoxyphenyl)ethyl]-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC1=C(C=CC(=C1)C=1C=NNC=1)N1C(N(CC1)[C@H](C)C1=CC(=CC=C1)OC)=O XTEIMRMVNBUQSJ-OAHLLOKOSA-N 0.000 description 1
- KQMNRLFJZUFDTR-OAHLLOKOSA-N 1-[(1R)-1-(3-methoxyphenyl)ethyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)[C@H](C)C1=CC(=CC=C1)OC)=O KQMNRLFJZUFDTR-OAHLLOKOSA-N 0.000 description 1
- LXEYNVHQNOXMQK-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound FC1=C(CN2C(N(CC2)C2=CC(=C(C=C2)C=2C=NNC=2)OC)=O)C(=CC=C1)F LXEYNVHQNOXMQK-UHFFFAOYSA-N 0.000 description 1
- FRCVRNZDCPEEQG-UHFFFAOYSA-N 1-[(2-fluoro-3-methoxyphenyl)methyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)CC1=C(C(=CC=C1)OC)F)=O FRCVRNZDCPEEQG-UHFFFAOYSA-N 0.000 description 1
- FRAKDSWLOARUNH-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC1=C(C=CC(=C1)N1CCN(CC2=C(F)C=CC=C2)C1=O)C1=CNN=C1 FRAKDSWLOARUNH-UHFFFAOYSA-N 0.000 description 1
- JVEFMTIWWVNIRU-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-4-carboxylic acid Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1C(=O)O)CC1=CC(=CC=C1)F)=O JVEFMTIWWVNIRU-UHFFFAOYSA-N 0.000 description 1
- HFJHECSDPULPIU-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound FC=1C=C(CN2C(N(CC2)C2=C(C=C(C=C2)C=2C=NNC=2)OC)=O)C=CC=1 HFJHECSDPULPIU-UHFFFAOYSA-N 0.000 description 1
- WGEUAXKQYVSRHY-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC1=C(C=CC(=C1)N1CCN(CC2=CC(F)=CC=C2)C1=O)C1=CNN=C1 WGEUAXKQYVSRHY-UHFFFAOYSA-N 0.000 description 1
- MUKLZKCIRDTYCM-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-4-(hydroxymethyl)-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1CO)CC1=CC(=CC=C1)F)=O MUKLZKCIRDTYCM-UHFFFAOYSA-N 0.000 description 1
- IWXDJTRBIGVMEG-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-4-carboxylic acid Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1C(=O)O)CC1=CC(=CC=C1)OC)=O IWXDJTRBIGVMEG-UHFFFAOYSA-N 0.000 description 1
- RKCCODFZRAFCMG-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC1=CC=CC(CN2CCN(C2=O)C2=CC(OC)=C(C=C2)C2=CNN=C2)=C1 RKCCODFZRAFCMG-UHFFFAOYSA-N 0.000 description 1
- BMEJPAZHWTWBKT-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1=O)CC1=CC(=CC=C1)OC)=O BMEJPAZHWTWBKT-UHFFFAOYSA-N 0.000 description 1
- CZOOOQPOAOPIDL-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]imidazol-2-one Chemical compound N1C=CC=2C1=NC=CC=2C1=CC=C(C=C1)N1C(N(C=C1)CC1=CC(=CC=C1)OC)=O CZOOOQPOAOPIDL-UHFFFAOYSA-N 0.000 description 1
- QISMYKJVOCVFLG-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]imidazolidin-2-one Chemical compound N1C=CC=2C1=NC=CC=2C1=CC=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O QISMYKJVOCVFLG-UHFFFAOYSA-N 0.000 description 1
- XAQWJBMIHYQAMU-UHFFFAOYSA-N 1-[(3-methoxyphenyl)methyl]-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl]imidazolidin-2-one Chemical compound N1=CN=C(C2=C1NC=C2)C1=CC=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O XAQWJBMIHYQAMU-UHFFFAOYSA-N 0.000 description 1
- VVEHBLSVDUDEBQ-UHFFFAOYSA-N 1-[1-(3-methoxyphenyl)-2-(methylamino)ethyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)C(CNC)C1=CC(=CC=C1)OC)=O VVEHBLSVDUDEBQ-UHFFFAOYSA-N 0.000 description 1
- YUFVWTLQOPZHKP-UHFFFAOYSA-N 1-[1-hydroxy-2-(3-methoxyphenyl)propan-2-yl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)C(CO)(C)C1=CC(=CC=C1)OC)=O YUFVWTLQOPZHKP-UHFFFAOYSA-N 0.000 description 1
- WJASCAQGZUNIRX-UHFFFAOYSA-N 1-[2-(2-fluorophenyl)ethyl]-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound FC1=C(CCN2C(N(CC2)C2=C(C=C(C=C2)C=2C=NNC=2)OC)=O)C=CC=C1 WJASCAQGZUNIRX-UHFFFAOYSA-N 0.000 description 1
- LWPSWPKLURSGJK-UHFFFAOYSA-N 1-[2-(2-methoxyphenyl)ethyl]-3-[4-(1H-pyrazol-4-yl)phenyl]imidazol-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C=C1)CCC1=C(C=CC=C1)OC)=O LWPSWPKLURSGJK-UHFFFAOYSA-N 0.000 description 1
- XGCROCOIBGNQTI-UHFFFAOYSA-N 1-[2-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound FC1=CC=C(CCN2C(N(CC2)C2=CC(=C(C=C2)C=2C=NNC=2)OC)=O)C=C1 XGCROCOIBGNQTI-UHFFFAOYSA-N 0.000 description 1
- HYEOCFWCWKJHQY-MRXNPFEDSA-N 1-[3-ethyl-4-(1H-pyrazol-4-yl)phenyl]-3-[(1R)-1-(3-methoxyphenyl)ethyl]imidazolidin-2-one Chemical compound C(C)C=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)[C@H](C)C1=CC(=CC=C1)OC)=O HYEOCFWCWKJHQY-MRXNPFEDSA-N 0.000 description 1
- IEOVIHKCZAPBIR-UHFFFAOYSA-N 1-[3-ethyl-4-(1H-pyrazol-4-yl)phenyl]-3-[(2-fluorophenyl)methyl]imidazolidin-2-one Chemical compound C(C)C=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)CC1=C(C=CC=C1)F)=O IEOVIHKCZAPBIR-UHFFFAOYSA-N 0.000 description 1
- CSPKLCFKIURJPC-UHFFFAOYSA-N 1-[3-ethyl-4-(1H-pyrazol-4-yl)phenyl]-3-[(3-fluorophenyl)methyl]imidazolidin-2-one Chemical compound C(C)C=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)CC1=CC(=CC=C1)F)=O CSPKLCFKIURJPC-UHFFFAOYSA-N 0.000 description 1
- ZMXBRPWXVIXAAF-UHFFFAOYSA-N 1-[3-ethyl-4-(1H-pyrazol-4-yl)phenyl]-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound C(C)C=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O ZMXBRPWXVIXAAF-UHFFFAOYSA-N 0.000 description 1
- WYJMOUGDPGZMCS-UHFFFAOYSA-N 1-[3-ethyl-4-(1H-pyrazol-4-yl)phenyl]-3-[2-(3-methoxyphenyl)ethyl]imidazolidin-2-one Chemical compound C(C)C=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)CCC1=CC(=CC=C1)OC)=O WYJMOUGDPGZMCS-UHFFFAOYSA-N 0.000 description 1
- HEJCJVHXTDWFJO-UHFFFAOYSA-N 1-[3-hydroxy-1-(3-methoxyphenyl)-3-methylbutyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound OC(CC(C1=CC(=CC=C1)OC)N1C(N(CC1)C1=CC(=C(C=C1)C=1C=NNC=1)OC)=O)(C)C HEJCJVHXTDWFJO-UHFFFAOYSA-N 0.000 description 1
- WZBRLPCQUOXSNO-UHFFFAOYSA-N 1-[3-hydroxy-1-(3-methoxyphenyl)propyl]-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound OCCC(C1=CC(=CC=C1)OC)N1C(N(CC1)C1=CC(=C(C=C1)C=1C=NNC=1)OC)=O WZBRLPCQUOXSNO-UHFFFAOYSA-N 0.000 description 1
- FNAYFJWFINCCCN-UHFFFAOYSA-N 1-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]-3-[[2-(1H-pyrazol-4-yl)phenyl]methyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=C(CN2C(N(CC2)C2=CC(=C(C=C2)C=2C=NNC=2)OC)=O)C=CC=C1 FNAYFJWFINCCCN-UHFFFAOYSA-N 0.000 description 1
- PYALLCMXWCFOCX-UHFFFAOYSA-N 1-[4-(2-aminopyridin-4-yl)phenyl]-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound NC1=NC=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O PYALLCMXWCFOCX-UHFFFAOYSA-N 0.000 description 1
- NXMVPMHQRPARFQ-UHFFFAOYSA-N 1-[4-(2-aminopyrimidin-4-yl)phenyl]-3-[(3-methoxyphenyl)methyl]imidazolidin-2-one Chemical compound NC1=NC=CC(=N1)C1=CC=C(C=C1)N1C(N(CC1)CC1=CC(=CC=C1)OC)=O NXMVPMHQRPARFQ-UHFFFAOYSA-N 0.000 description 1
- BNAOBLINABTTSO-UHFFFAOYSA-N 1-benzyl-3-(4-bromophenyl)-4-(hydroxymethyl)imidazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(N(C(C1)CO)C1=CC=C(C=C1)Br)=O BNAOBLINABTTSO-UHFFFAOYSA-N 0.000 description 1
- UFARZHULZNJGDE-UHFFFAOYSA-N 1-benzyl-3-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(N(CC1)C1=C(C=C(C=C1)C=1C=NNC=1)OC)=O UFARZHULZNJGDE-UHFFFAOYSA-N 0.000 description 1
- CZCPSFBOZOSXND-UHFFFAOYSA-N 1-benzyl-3-[3-ethyl-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(N(CC1)C1=CC(=C(C=C1)C=1C=NNC=1)CC)=O CZCPSFBOZOSXND-UHFFFAOYSA-N 0.000 description 1
- LPXPDXVUMPDTEP-UHFFFAOYSA-N 1-benzyl-3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound COC1=C(C=CC(=C1)N1CCN(CC2=CC=CC=C2)C1=O)C1=CNN=C1 LPXPDXVUMPDTEP-UHFFFAOYSA-N 0.000 description 1
- FLXJPPGGLXLDJM-UHFFFAOYSA-N 1-benzyl-4-(hydroxymethyl)-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1CO)CC1=CC=CC=C1)=O FLXJPPGGLXLDJM-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- FDCHHLBMDMJXGM-UHFFFAOYSA-N 1-fluoro-4-(2-isocyanatoethyl)benzene Chemical compound FC1=CC=C(CCN=C=O)C=C1 FDCHHLBMDMJXGM-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- VKQVMEOGLGJQSF-UHFFFAOYSA-N 2-(3-methoxyphenyl)-2-[2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-1-yl]acetic acid Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1)C(C(=O)O)C1=CC(=CC=C1)OC)=O VKQVMEOGLGJQSF-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- RZELRWJJAXTINL-UHFFFAOYSA-N 2-[3-(4-bromophenyl)-2-oxoimidazolidin-1-yl]-2-(3-methoxyphenyl)-N-methylpropanamide Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1)C(C(=O)NC)(C)C1=CC(=CC=C1)OC)=O RZELRWJJAXTINL-UHFFFAOYSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 1
- CAAMSDWKXXPUJR-UHFFFAOYSA-N 3,5-dihydro-4H-imidazol-4-one Chemical compound O=C1CNC=N1 CAAMSDWKXXPUJR-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- WWUAAPGMDKZRPZ-UHFFFAOYSA-N 3-(3-methoxyphenyl)-3-[3-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]-2-oxoimidazolidin-1-yl]propanoic acid Chemical compound COC=1C=C(C=CC=1C=1C=NNC=1)N1C(N(CC1)C(CC(=O)O)C1=CC(=CC=C1)OC)=O WWUAAPGMDKZRPZ-UHFFFAOYSA-N 0.000 description 1
- LRSUMZGSORKIJR-UHFFFAOYSA-N 3-(4-bromophenyl)-1-[(3-methoxyphenyl)methyl]imidazolidine-2,4-dione Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1=O)CC1=CC(=CC=C1)OC)=O LRSUMZGSORKIJR-UHFFFAOYSA-N 0.000 description 1
- FPFDMHRKTCRRBC-UHFFFAOYSA-N 3-(4-bromophenyl)imidazolidine-2,4-dione Chemical compound C1=CC(Br)=CC=C1N1C(=O)NCC1=O FPFDMHRKTCRRBC-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NRXLNOGWWFSOTE-UHFFFAOYSA-N 3-[(3-fluorophenyl)methyl]-2-oxo-1-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-4-carboxylic acid Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C(C1)C(=O)O)CC1=CC(=CC=C1)F)=O NRXLNOGWWFSOTE-UHFFFAOYSA-N 0.000 description 1
- PYXRSVHHYDHINP-UHFFFAOYSA-N 3-benzyl-1-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidine-2,4-dione Chemical compound C(C1=CC=CC=C1)N1C(N(CC1=O)C1=CC(=C(C=C1)C=1C=NNC=1)OC)=O PYXRSVHHYDHINP-UHFFFAOYSA-N 0.000 description 1
- NDWIDQDXARXUKA-UHFFFAOYSA-N 3-benzyl-4-(hydroxymethyl)-1-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound C(C1=CC=CC=C1)N1C(N(CC1CO)C1=CC(=C(C=C1)C=1C=NNC=1)OC)=O NDWIDQDXARXUKA-UHFFFAOYSA-N 0.000 description 1
- PJNUHHGFVZSTRI-UHFFFAOYSA-N 3-benzyl-4-(hydroxymethyl)-1-[4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(C(C1)CO)CC1=CC=CC=C1)=O PJNUHHGFVZSTRI-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- XRLJROQMXLOJFO-UHFFFAOYSA-N 4-(bromomethyl)-1-fluoro-2-methoxybenzene Chemical compound COC1=CC(CBr)=CC=C1F XRLJROQMXLOJFO-UHFFFAOYSA-N 0.000 description 1
- YANQUJBGDOPLFF-UHFFFAOYSA-N 4-(hydroxymethyl)-3-[(3-methoxyphenyl)methyl]-1-[3-methoxy-4-(1H-pyrazol-4-yl)phenyl]imidazolidin-2-one Chemical compound OCC1N(C(N(C1)C1=CC(=C(C=C1)C=1C=NNC=1)OC)=O)CC1=CC(=CC=C1)OC YANQUJBGDOPLFF-UHFFFAOYSA-N 0.000 description 1
- LEZHTYOQWQEBLH-UHFFFAOYSA-N 4-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CC=NC2=C1C=CN2 LEZHTYOQWQEBLH-UHFFFAOYSA-N 0.000 description 1
- KWQNNOZROOJVJB-UHFFFAOYSA-N 4-bromo-3-ethylaniline Chemical compound CCC1=CC(N)=CC=C1Br KWQNNOZROOJVJB-UHFFFAOYSA-N 0.000 description 1
- VXOFSWLIUSBFDH-UHFFFAOYSA-N 4-bromo-N-(2-chloroethyl)-3-ethylaniline Chemical compound BrC1=C(C=C(NCCCl)C=C1)CC VXOFSWLIUSBFDH-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-IDEBNGHGSA-N 4-bromoaniline Chemical group N[13C]1=[13CH][13CH]=[13C](Br)[13CH]=[13CH]1 WDFQBORIUYODSI-IDEBNGHGSA-N 0.000 description 1
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- GGHBRLQYBZMEPV-UHFFFAOYSA-N 5-bromo-4-fluoropyridin-2-amine Chemical compound NC1=CC(F)=C(Br)C=N1 GGHBRLQYBZMEPV-UHFFFAOYSA-N 0.000 description 1
- JDNCMHOKWINDKI-UHFFFAOYSA-N 5-bromo-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1Br JDNCMHOKWINDKI-UHFFFAOYSA-N 0.000 description 1
- STTFWVSVDMLUCF-UHFFFAOYSA-N 5-bromo-6-methoxypyridin-2-amine Chemical compound COC1=NC(N)=CC=C1Br STTFWVSVDMLUCF-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 102100023818 ADP-ribosylation factor 3 Human genes 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- UMYTZPUJKKRUDX-CYBMUJFWSA-N BrC1=CC=C(C=C1)N1C(N[C@H](C1)CO[Si](C)(C)C(C)(C)C)=O Chemical compound BrC1=CC=C(C=C1)N1C(N[C@H](C1)CO[Si](C)(C)C(C)(C)C)=O UMYTZPUJKKRUDX-CYBMUJFWSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- VNBXBHYGOAGGOG-UHFFFAOYSA-N COC=1C=C(CN2C(N(C=C2)C2=CC=C(C=C2)B2OC(C(O2)(C)C)(C)C)=O)C=CC=1 Chemical compound COC=1C=C(CN2C(N(C=C2)C2=CC=C(C=C2)B2OC(C(O2)(C)C)(C)C)=O)C=CC=1 VNBXBHYGOAGGOG-UHFFFAOYSA-N 0.000 description 1
- BNQQJIRZGZUKEJ-UHFFFAOYSA-N COC=1C=C(CN2C(N(CC2)C2=CC=C(C=C2)B2OC(C(O2)(C)C)(C)C)=O)C=CC=1 Chemical compound COC=1C=C(CN2C(N(CC2)C2=CC=C(C=C2)B2OC(C(O2)(C)C)(C)C)=O)C=CC=1 BNQQJIRZGZUKEJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241001000171 Chira Species 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- XNLWZFDLOBDYSS-UHFFFAOYSA-M FC(S(=O)(=O)[O-])(F)F.[Rh+].C1=CCCC=CCC1.C1=CC=CC=C1 Chemical compound FC(S(=O)(=O)[O-])(F)F.[Rh+].C1=CCCC=CCC1.C1=CC=CC=C1 XNLWZFDLOBDYSS-UHFFFAOYSA-M 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000684275 Homo sapiens ADP-ribosylation factor 3 Proteins 0.000 description 1
- 101001000061 Homo sapiens Protein phosphatase 1 regulatory subunit 12A Proteins 0.000 description 1
- 101001130437 Homo sapiens Ras-related protein Rap-2b Proteins 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 description 1
- GSCCALZHGUWNJW-UHFFFAOYSA-N N-Cyclohexyl-N-methylcyclohexanamine Chemical compound C1CCCCC1N(C)C1CCCCC1 GSCCALZHGUWNJW-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100036547 Protein phosphatase 1 regulatory subunit 12A Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000050488 Urotensin II Human genes 0.000 description 1
- 108010018369 Urotensin II Proteins 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WGOBPPNNYVSJTE-HSZRJFAPSA-N [(2r)-1-diphenylphosphanylpropan-2-yl]-diphenylphosphane Chemical compound C([C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)P(C=1C=CC=CC=1)C1=CC=CC=C1 WGOBPPNNYVSJTE-HSZRJFAPSA-N 0.000 description 1
- UJQAHAANAPEYLR-UHFFFAOYSA-N [2-chloro-6-[2,4,6-tri(propan-2-yl)phenyl]phenyl]-dicyclohexylphosphane Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC(Cl)=C1P(C1CCCCC1)C1CCCCC1 UJQAHAANAPEYLR-UHFFFAOYSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000005512 benztetrazolyl group Chemical group 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 208000037998 chronic venous disease Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- ASWXNYNXAOQCCD-UHFFFAOYSA-N dichloro(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Cl)(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 ASWXNYNXAOQCCD-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- DYTUEMCDMKQUGA-UHFFFAOYSA-N ethyl 1-(4-bromophenyl)-3-[(3-fluorophenyl)methyl]-2-oxoimidazolidine-4-carboxylate Chemical compound BrC1=CC=C(C=C1)N1C(N(C(C1)C(=O)OCC)CC1=CC(=CC=C1)F)=O DYTUEMCDMKQUGA-UHFFFAOYSA-N 0.000 description 1
- RCPLGAPSWVOJNE-UHFFFAOYSA-N ethyl 1-[(3-methoxyphenyl)methyl]-2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-4-carboxylate Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1C(=O)OCC)CC1=CC(=CC=C1)OC)=O RCPLGAPSWVOJNE-UHFFFAOYSA-N 0.000 description 1
- NRFKMJQVWJLUDU-UHFFFAOYSA-N ethyl 1-benzyl-2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-4-carboxylate Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1C(=O)OCC)CC1=CC=CC=C1)=O NRFKMJQVWJLUDU-UHFFFAOYSA-N 0.000 description 1
- QEULPJZBADJNAU-UHFFFAOYSA-N ethyl 1-benzyl-3-(4-bromophenyl)-2-oxoimidazolidine-4-carboxylate Chemical compound C(C1=CC=CC=C1)N1C(N(C(C1)C(=O)OCC)C1=CC=C(C=C1)Br)=O QEULPJZBADJNAU-UHFFFAOYSA-N 0.000 description 1
- NTNZTEQNFHNYBC-UHFFFAOYSA-N ethyl 2-aminoacetate Chemical compound CCOC(=O)CN NTNZTEQNFHNYBC-UHFFFAOYSA-N 0.000 description 1
- AMLWQSYZUFWMJI-UHFFFAOYSA-N ethyl 3-(benzylamino)-2-chloropropanoate Chemical compound C(C1=CC=CC=C1)NCC(C(=O)OCC)Cl AMLWQSYZUFWMJI-UHFFFAOYSA-N 0.000 description 1
- OJGRWMKNEOUTSP-UHFFFAOYSA-N ethyl 3-[(4-bromophenyl)carbamoyl-[(3-fluorophenyl)methyl]amino]-2-chloropropanoate Chemical compound BrC1=CC=C(C=C1)NC(N(CC1=CC(=CC=C1)F)CC(C(=O)OCC)Cl)=O OJGRWMKNEOUTSP-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004995 haloalkylthio group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005283 haloketone group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 150000004680 hydrogen peroxides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- UPIBKDSLZYCEGT-UHFFFAOYSA-N methyl 1-[(3-fluorophenyl)methyl]-2-oxo-3-[4-(1H-pyrazol-4-yl)phenyl]imidazolidine-4-carboxylate Chemical compound N1N=CC(=C1)C1=CC=C(C=C1)N1C(N(CC1C(=O)OC)CC1=CC(=CC=C1)F)=O UPIBKDSLZYCEGT-UHFFFAOYSA-N 0.000 description 1
- TYYPCXSXKVPRQJ-UHFFFAOYSA-N methyl 3-(4-bromophenyl)-1-[(3-fluorophenyl)methyl]-2-oxoimidazolidine-4-carboxylate Chemical compound BrC1=CC=C(C=C1)N1C(N(CC1C(=O)OC)CC1=CC(=CC=C1)F)=O TYYPCXSXKVPRQJ-UHFFFAOYSA-N 0.000 description 1
- SCQXGTAVEQAZKX-UHFFFAOYSA-N methyl 3-[3-(4-bromo-3-methoxyphenyl)-2-oxoimidazolidin-1-yl]-3-(3-methoxyphenyl)propanoate Chemical compound BrC1=C(C=C(C=C1)N1C(N(CC1)C(CC(=O)OC)C1=CC(=CC=C1)OC)=O)OC SCQXGTAVEQAZKX-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000005009 overhauser spectroscopy Methods 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000008048 phenylpyrazoles Chemical class 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012041 precatalyst Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000016487 regulation of smooth muscle contraction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- IPISOFJLWYBCAV-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate Chemical compound C1=NN(C(=O)OC(C)(C)C)C=C1B1OC(C)(C)C(C)(C)O1 IPISOFJLWYBCAV-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000005403 thiohaloalkoxy group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101434P | 2015-01-09 | 2015-01-09 | |
| PCT/US2016/012560 WO2016112236A1 (en) | 2015-01-09 | 2016-01-08 | Cyclic ureas as inhibitors of rock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2815681T3 true ES2815681T3 (es) | 2021-03-30 |
Family
ID=55310909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16703378T Active ES2815681T3 (es) | 2015-01-09 | 2016-01-08 | Ureas cíclicas como inhibidores de ROCK |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10123993B2 (enExample) |
| EP (1) | EP3242873B1 (enExample) |
| JP (1) | JP6779214B2 (enExample) |
| CN (1) | CN107406426B (enExample) |
| AR (1) | AR103990A1 (enExample) |
| ES (1) | ES2815681T3 (enExample) |
| TW (1) | TW201630899A (enExample) |
| WO (1) | WO2016112236A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016112236A1 (en) | 2015-01-09 | 2016-07-14 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
| WO2016144936A1 (en) | 2015-03-09 | 2016-09-15 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| WO2017046739A1 (en) * | 2015-09-15 | 2017-03-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazolidinone derivatives as inhibitors of perk |
| AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
| JP6987792B2 (ja) * | 2016-05-27 | 2022-01-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン |
| ES2821877T3 (es) | 2016-07-07 | 2021-04-28 | Bristol Myers Squibb Co | Espirolactamas como inhibidores de ROCK |
| CN110049977B (zh) | 2016-07-07 | 2022-01-18 | 百时美施贵宝公司 | 作为强效和选择性rock抑制剂的内酰胺、环状脲和氨基甲酸酯及三唑酮衍生物 |
| ES2829550T3 (es) | 2016-07-07 | 2021-06-01 | Bristol Myers Squibb Co | Ureas cíclicas espiro-condensadas como inhibidores de ROCK |
| KR102511441B1 (ko) * | 2016-11-30 | 2023-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 트리시클릭 Rho 키나제 억제제 |
| JP7206253B2 (ja) | 2017-07-12 | 2023-01-17 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのフェニルアセトアミド |
| TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| JP7313331B2 (ja) | 2017-07-12 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロヘプタニルヒダントイン |
| US12060341B2 (en) | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| KR102680160B1 (ko) | 2017-07-12 | 2024-06-28 | 브리스톨-마이어스 스큅 컴퍼니 | 심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제 |
| WO2019089868A1 (en) * | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN112759550A (zh) * | 2019-11-04 | 2021-05-07 | 上海科技大学 | 一种平滑受体拮抗剂 |
| JP2021183586A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2023085369A1 (ja) | 2021-11-11 | 2023-05-19 | 学校法人同志社 | 角膜内皮細胞の凍結保存製剤およびその製造法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120424050A (zh) * | 2024-02-05 | 2025-08-05 | 科辉智药(深圳)新药研究中心有限公司 | 作为sarm1酶活性抑制剂的吡啶类化合物及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07183769A (ja) * | 1993-12-22 | 1995-07-21 | Fuji Electric Co Ltd | ラッチ回路 |
| EP1713775A4 (en) | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| WO2006048727A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| CN101253152A (zh) * | 2005-09-02 | 2008-08-27 | 安斯泰来制药株式会社 | 作为rock抑制剂的酰胺衍生物 |
| WO2009078992A1 (en) * | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| US20100269466A1 (en) * | 2007-12-17 | 2010-10-28 | Peshina William F | Oval cage coupler for filter cages |
| WO2010036316A1 (en) * | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| JP5769326B2 (ja) * | 2010-10-19 | 2015-08-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｈｏキナーゼ阻害薬 |
| CA2898440A1 (en) | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
| JP6423372B2 (ja) * | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体 |
| AR094929A1 (es) * | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| CN105492444B (zh) | 2013-07-02 | 2018-09-07 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
| EP3016950B1 (en) | 2013-07-02 | 2017-06-07 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| CN109021022B (zh) | 2013-07-31 | 2021-04-16 | Udc 爱尔兰有限责任公司 | 发光的二氮杂苯并咪唑碳烯金属配合物 |
| US9682960B2 (en) | 2013-12-19 | 2017-06-20 | Endorecherche, Inc. | Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety |
| RU2016131875A (ru) * | 2014-01-20 | 2018-02-26 | Ф. Хоффманн-Ля Рош Аг | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| WO2016112236A1 (en) | 2015-01-09 | 2016-07-14 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
| WO2016144936A1 (en) | 2015-03-09 | 2016-09-15 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| AR107354A1 (es) | 2016-01-13 | 2018-04-18 | Bristol Myers Squibb Co | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock |
-
2016
- 2016-01-08 WO PCT/US2016/012560 patent/WO2016112236A1/en not_active Ceased
- 2016-01-08 AR ARP160100053A patent/AR103990A1/es unknown
- 2016-01-08 CN CN201680012270.1A patent/CN107406426B/zh active Active
- 2016-01-08 ES ES16703378T patent/ES2815681T3/es active Active
- 2016-01-08 JP JP2017536259A patent/JP6779214B2/ja active Active
- 2016-01-08 EP EP16703378.6A patent/EP3242873B1/en active Active
- 2016-01-08 US US15/541,725 patent/US10123993B2/en active Active
- 2016-01-08 TW TW105100631A patent/TW201630899A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180000788A1 (en) | 2018-01-04 |
| JP6779214B2 (ja) | 2020-11-04 |
| TW201630899A (zh) | 2016-09-01 |
| AR103990A1 (es) | 2017-06-21 |
| EP3242873B1 (en) | 2020-07-22 |
| WO2016112236A1 (en) | 2016-07-14 |
| US10123993B2 (en) | 2018-11-13 |
| CN107406426B (zh) | 2020-11-20 |
| CN107406426A (zh) | 2017-11-28 |
| EP3242873A1 (en) | 2017-11-15 |
| JP2018501285A (ja) | 2018-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2815681T3 (es) | Ureas cíclicas como inhibidores de ROCK | |
| ES2814325T3 (es) | Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK | |
| ES2781309T3 (es) | Triazolonas y tetrazolonas como inhibidores de ROCK | |
| ES2829550T3 (es) | Ureas cíclicas espiro-condensadas como inhibidores de ROCK | |
| ES2821877T3 (es) | Espirolactamas como inhibidores de ROCK | |
| ES2937039T3 (es) | Inhibidores diazaespiro de ROCK | |
| ES2684776T3 (es) | Ftalazinonas e isoquinolinonas como inhibidores de ROCK | |
| ES2730112T3 (es) | Lactamas como inhibidores de ROCK | |
| ES2838573T3 (es) | Derivados de benzamida ligados como inhibidores potentes de ROCK | |
| ES2634628T3 (es) | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK | |
| ES2951212T3 (es) | Fenilacetamidas como inhibidores de ROCK | |
| ES2829400T3 (es) | Inhibidores tricíclicos de Rho cinasa | |
| ES2882432T3 (es) | Amidas de 5 miembros y heterocíclicas bicíclicas como inhibidores de ROCK | |
| ES2712699T3 (es) | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa | |
| ES2894128T3 (es) | Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca | |
| EP2961745A1 (en) | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors | |
| EP2961746A1 (en) | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors | |
| TW202334167A (zh) | 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物 |